Treatment outcomes and patient-reported quality of life after orthognathic surgery with computer-assisted 2-or 3-dimensional planning: A randomized double-blind active-controlled clinical trial

被引:21
|
作者
Bengtsson, Martin [1 ]
Wall, Gert [1 ]
Larsson, Pernilla [2 ,3 ]
Becktor, Jonas P. [4 ]
Rasmusson, Lars [5 ]
机构
[1] Univ Hosp Skane, Dept Oral & Maxillofacial Surg, S-22185 Lund, Sweden
[2] Ostergotland Cty Council, Ctr Oral Rehabil, Linkoping, Sweden
[3] Malmo Univ, Fac Odontol, Dept Orofacial Pain & Jaw Funct, Malmo, Sweden
[4] Malmo Univ, Fac Odontol, Dept Oral & Maxillofacial Surg & Oral Med, Malmo, Sweden
[5] Gothenburg Univ, Sahlgrenska Acad, Dept Oral & Maxillofacial Surg, Gothenburg, Sweden
关键词
OROFACIAL AESTHETIC SCALE; CAD/CAM SURGICAL SPLINTS; DISTRACTION OSTEOGENESIS; PROSTHODONTIC PATIENTS; SWEDISH VERSION; ACCURACY; SIMULATION; IMPACT; RELIABILITY; VALIDITY;
D O I
10.1016/j.ajodo.2017.12.008
中图分类号
R78 [口腔科学];
学科分类号
1003 ;
摘要
Introduction: Thorough treatment planning is essential for a good clinical outcome in orthognathic treatment. The planning is often digital. Both 2-dimensional (2D) and 3-dimensional (3D) software options are available. The aim of this randomized 2-arm parallel double-blinded active-controlled clinical trial was to comprae the outcomes of computer-based 2D and 3D planning techniques according to patient-reported health related quality of life. The hypothesis was that a 3D technique would give a better treatment outcome compared with a 2D technique. Methods: Orthognathic treatment for 62 subjects, aged 18 to 28 years, with severe Class III malocclusion was planned with both 2D and 3D techniques. After treatment planning but before surgery, the patients were randomly allocated via blind collection of 1 enveloped card for each subject in a 1:1 ratio to the test (3D) or the control (2D) group. Thus, the intervention was according to which planning technique was used. The primary outcome was patient-reported outcome measures. The secondary outcome was relationship between patient-reported outcome measures and cephalometric accuracy. Questionnaires on the patient's health-related quality of life (HRQoL) were distributed preoperatively and 12 months after surgical treatment. The questionnaires were coded, meaning blinding throughout the analysis. Differences between groups were tested with the Fisher permutation test. The HRQoL was also compared with measurements of cephalometric accuracy for the 2 groups. Reslts: Three subjects were lost to clinical follow-up leaving 57 included. Of these, 55 subjects completed the questionnaires, 28 in the 2D and 27 in the 3D groups. No statistically significant difference regarding HRQoL was found between the studied planning techniques: the Oral Health Impact Profile total showed -3.69 (95% confidence interval, -19.68 to 12.30). Consistent results on HRQoL and cephalometric accuracy showed a difference between pretreatment and postreatment that increased in both groups but to a higher level in the 3D group. A difference between pretreatment and posttreatment HRQoL was shown for both groups, indicating increased quality of life after treatment. This supports recent findings comparing 3D and 2D planning techniques. No serious harm was observed during the study. Conclusions: Improvemens of HRQoL were shown after treatment independent of which planning technique, 2D or 3D, was used. No statisticaly significant difference was found between the planning techniqes. Registration: This trial was not registered. Protocol: The protocol was not published before trial commencement.
引用
收藏
页码:786 / 796
页数:11
相关论文
共 47 条
  • [31] IMPROVEMENTS IN PATIENT-REPORTED OUTCOMES FOLLOWING 52 WEEKS OF TREATMENT WITH CERTOLIZUMAB PEGOL IN COMBINATION WITH METHOTREXATE IN DMARD-NAIVE PATIENTS WITH SEVERE, ACTIVE AND PROGRESSIVE RHEUMATOID ARTHRITIS: RESULTS FROM THE C-EARLY RANDOMIZED, DOUBLE-BLIND, CONTROLLED PHASE 3 STUDY
    Emery, P.
    Bingham, C.
    Burmester, G.
    Bykerk, V
    Furst, D.
    Mariette, X.
    Purcaru, O.
    Coteur, G.
    Vanlunen, B.
    Weinblatt, M.
    VALUE IN HEALTH, 2015, 18 (07) : A707 - A708
  • [32] AN EPISODE-BASED, PATIENT-REPORTED OUTCOME MEASURE OF DYSPHAGIA ACCURATELY CAPTURES RESPONSE TO TREATMENT WITH APT-1011 IN A PHASE 2B, RANDOMIZED, DOUBLE-BLIND, PLACEBOCONTROLLED, CLINICAL TRIAL IN ADULTS WITH EOSINOPHILIC ESOPHAGITIS
    Dellon, Evan S.
    Falk, Gary W.
    Hirano, Ikuo
    Lucendo, Alfredo
    Schlag, Christoph
    Schoepfer, Alain M.
    Eagle, Gina
    Nezamis, James P.
    Sparling, Nicole
    Richardson, Peter
    Knoop, Karol
    Paty, Jean
    GASTROENTEROLOGY, 2020, 158 (06) : S817 - S817
  • [33] Patient-Reported Outcomes from the Phase 3 Randomized, Double-Blind, KEYNOTE-826 Trial of Pembrolizumab Plus Chemotherapy Versus Placebo Plus Chemotherapy for the First-Line Treatment of Persistent, Recurrent, or Metastatic Cervical Cancer
    Monk, Bradley
    Tewari, Krishnansu
    Dubot, Coraline
    Caceres, M. Valeria
    Hasegawa, Kosei
    Shapira-Frommer, Ronnie
    Salman, Pamela
    Yanez, Eduardo
    Gumus, Mahmut
    De Mendoza, Mivael Olivera Hurtado
    Samouelian, Vanessa
    Castonguay, Vincent
    Arkhipov, Alexander
    Tekin, Cumhur
    Li, Kan
    Nguyen, Allison Martin
    Monberg, Matthew
    Colombo, Nicoletta
    Lorusso, Domenica
    GYNECOLOGIC ONCOLOGY, 2022, 166 : S18 - S18
  • [34] Twice-Daily Balsalazide Tablets Improve Patient Quality of Life After 2, 6, or 8 Weeks of Treatment: Results of Two Phase 3, Randomized, Double-Blind Multicenter Studies
    Rosen, Alana A.
    Sedghi, Shahriar
    Shepard, Roland D.
    Mareya, Shadreck M.
    Huang, Shirley
    Shaw, Audrey L.
    Forbes, William P.
    GASTROENTEROLOGY, 2009, 136 (05) : A522 - A522
  • [35] Effect of Omega-3 Fatty Acids Supplementation on Depressive Symptoms and on Health-Related Quality of Life in the Treatment of Elderly Women with Depression: A Double-Blind, Placebo-Controlled, Randomized Clinical Trial
    Rondanelli, Mariangela
    Giacosa, Attilio
    Opizzi, Annalisa
    Pelucchi, Claudio
    La Vecchia, Carlo
    Montorfano, Gigliola
    Negroni, Manuela
    Berra, Bruno
    Politi, Pierluigi
    Rizzo, Angela Maria
    JOURNAL OF THE AMERICAN COLLEGE OF NUTRITION, 2010, 29 (01) : 55 - 64
  • [36] ANALYSIS OF PATIENT-REPORTED OUTCOMES FROM THE LUME-LUNG 1 TRIAL: A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED PHASE 3 STUDY IN SECOND-LINE ADVANCED NON-SMALL CELL LUNG CANCER (NSCLC) PATIENTS
    Novello, Silvia
    Mellemgaard, Anders
    Kaiser, Rolf
    Douillard, Jean-Yves
    Orlov, Sergei
    Krzakowski, Maciej
    Von Pawel, Joachim
    Gottfried, Maya
    Bondarenko, Igor
    Liao, Meilin
    Barrueco, Jose
    Gaschler-Markefski, Birgit
    Griebsch, Ingolf
    Reck, Martin
    JOURNAL OF THORACIC ONCOLOGY, 2013, 8 : S1207 - S1207
  • [37] Improvement in patient-reported hair loss outcome measures in patients with alopecia areata treated with ritlecitinib: 48-week results from the ALLEGRO phase 2b/3 randomized, double-blind, placebo-controlled trial
    Sinclair, Rodney
    Mesinkovska, Natasha
    Mitra, Debanjali
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2022, 87 (03) : AB69 - AB69
  • [38] Capivasertib and fulvestrant for patients with hormone receptor-positive, HER2-negative advanced breast cancer (CAPItello-291): patient-reported outcomes from a phase 3, randomised, double-blind, placebo-controlled trial
    Oliveira, Mafalda
    Rugo, Hope S.
    Howell, Sacha J.
    Dalenc, Florence
    Cortes, Javier
    Gomez, Henry L.
    Hu, Xichun
    Toi, Masakazu
    Jhaveri, Komal
    Krivorotko, Petr
    Loibl, Sibylle
    Murillo, Serafin Morales
    Okera, Meena
    Nowecki, Zbigniew
    Park, Yeon Hee
    Sohn, Joo Hyuk
    Tokunaga, Eriko
    Yousef, Samih
    Zhukova, Lyudmila
    Fulford, Marta
    Andrews, Haylee
    Wadsworth, Ian
    D'Cruz, Celina
    Turner, Nicholas C.
    LANCET ONCOLOGY, 2024, 25 (09): : 1231 - 1244
  • [39] The ECHELON-2 Trial: Results of a Randomized, Double-Blind, Active-Controlled Phase 3 Study of Brentuximab Vedotin and CHP (A plus CHP) Versus CHOP in the Frontline Treatment of Patients with CD30+Peripheral T-Cell Lymphomas
    Horwitz, Steven M.
    O'Connor, Owen A.
    Pro, Barbara
    Illidge, Tim M.
    Fanale, Michelle A.
    Advani, Ranjana H.
    Bartlett, Nancy L.
    Christensen, Jacob Haaber
    Morschhauser, Franck
    Domingo-Domenech, Eva
    Rossi, Giuseppe
    Kim, Won Seog
    Feldman, Tatyana A.
    Lennard, Anne
    Belada, David
    Illes, Arpad
    Tobinai, Kensei
    Tsukasaki, Kunihiro
    Yeh, Su-Peng
    Shustov, Andrei R.
    Huettmann, Andreas
    Savage, Kerry J.
    Yuen, Sam
    Zinzani, Pier Luigi
    Hua, Zhaowei
    Little, Meredith
    Rao, Shangbang
    Woolery, Joseph
    Manley, Thomas
    Truemper, Lorenz
    BLOOD, 2018, 132